Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1979 1
1980 2
1986 1
1988 2
1989 1
1990 2
1991 2
1992 1
1993 2
1994 1
1995 3
2002 2
2004 1
2007 2
2008 1
2009 1
2013 1
2014 1
2018 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Antithrombin.
Hepner M, Karlaftis V. Hepner M, et al. Methods Mol Biol. 2013;992:355-64. doi: 10.1007/978-1-62703-339-8_28. Methods Mol Biol. 2013. PMID: 23546728
Antithrombin (AT) is a heparin cofactor and a member of the serine protease inhibitor family (serpin). ...Initially, several different AT activities in plasma were reported, leading to the classification of antithrombin in a range from I to IV. It was subsequ
Antithrombin (AT) is a heparin cofactor and a member of the serine protease inhibitor family (serpin). ...Initially, several d
Revisiting antithrombin in health and disease, congenital deficiencies and genetic variants, and laboratory studies on alpha and beta forms.
Amiral J, Seghatchian J. Amiral J, et al. Transfus Apher Sci. 2018 Apr;57(2):291-297. doi: 10.1016/j.transci.2018.04.010. Epub 2018 Apr 19. Transfus Apher Sci. 2018. PMID: 29784539 Review.
Antithrombin [AT] is the main inhibitor for activated plasma coagulation serine esterases, inhibiting thrombin, Factors Xa and IXa, but also Factors XIIa, XIa, VIIa, kallicrein, and plasmin. Its activity is highly enhanced by heparin, through binding to the p
Antithrombin [AT] is the main inhibitor for activated plasma coagulation serine esterases, inhibiting thrombin, Factors Xa and IXa, b
Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits.
Tazawa S, Ichikawa K, Misawa K, Fukuyama J, Hamano S, Miyata H, Sakuragawa N. Tazawa S, et al. Thromb Res. 1995 Dec 1;80(5):391-8. doi: 10.1016/0049-3848(95)00191-s. Thromb Res. 1995. PMID: 8588200
The effect of dalteparin, a low molecular weight heparin, on severely antithrombin III (ATIII)-decreased disseminated intravascular coagulation (DIC) model was compared with that of unfractionated heparin (heparin). ...However, the increased rat …
The effect of dalteparin, a low molecular weight heparin, on severely antithrombin III (ATIII)-decreased disseminated i …
Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio.
Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H. Kario K, et al. Haemostasis. 1992;22(4):179-86. doi: 10.1159/000216317. Haemostasis. 1992. PMID: 1468720
Plasma thrombin-antithrombin-III complex (TAT) and plasmin-alpha 2-antiplasmin complex (PAP) levels were measured in 133 blood samples obtained from patients with DIC. ...However, in severe DIC, the ratio decreased, and plasmin activity became excessiv …
Plasma thrombin-antithrombin-III complex (TAT) and plasmin-alpha 2-antiplasmin complex (PAP) levels were measured in 13 …
Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations.
Yamada S, Asakura H. Yamada S, et al. Int J Hematol. 2021 Jan;113(1):15-23. doi: 10.1007/s12185-020-03028-z. Epub 2020 Nov 11. Int J Hematol. 2021. PMID: 33175341 Review.
A typical blood coagulation test shows decrease in platelet count and fibrinogen, and increases in fibrin/fibrinogen degradation products (FDP) and D-dimer. The coagulation activation marker thrombin-antithrombin complex (TAT) and the fibrinolysis activation marker plas
A typical blood coagulation test shows decrease in platelet count and fibrinogen, and increases in fibrin/fibrinogen degradation products (F …
The proteinase inhibitor complexes (antithrombin III-thrombin, alpha 2antiplasmin-plasmin and alpha 1antitrypsin-elastase) in septicemia, fulminant hepatic failure and cardiac shock: value for diagnosis and therapy control in DIC/F syndrome.
Egbring R, Seitz R, Blanke H, Leititis J, Kesper HJ, Burghard R, Fuchs G, Lerch L. Egbring R, et al. Behring Inst Mitt. 1986 Feb;(79):87-103. Behring Inst Mitt. 1986. PMID: 2424425
Thrombin (Thr), plasmin (Pl) and elastase (ELP) are serine proteinases which are quickly inactivated by their specific inhibitors (AT III, alpha 2AP, alpha 1AT), if intravascular activation of coagulation and fibrinolytic system or if release from PMN granulocytes b …
Thrombin (Thr), plasmin (Pl) and elastase (ELP) are serine proteinases which are quickly inactivated by their specific inhibitors (AT …
The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
Gram J. Gram J. Dan Med Bull. 1990 Jun;37(3):210-34. Dan Med Bull. 1990. PMID: 2192835 Review.
Inhibition of coagulation impairs its progression and the non-thrombogenic nature of the normal endothelium is chiefly caused by the binding of inhibitory components (antithrombin-III, protein C) to specific receptor sites. Physiological activation of fibrinolysis a …
Inhibition of coagulation impairs its progression and the non-thrombogenic nature of the normal endothelium is chiefly caused by the binding …
Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
Jespersen J. Jespersen J. Dan Med Bull. 1988 Feb;35(1):1-33. Dan Med Bull. 1988. PMID: 3277796 Review.
(ABSTRACT TRUNCATED AT 400 WORDS) A detailed review of the dynamic processes of coagulation and fibrinolysis precedes a discussion of clinical applications, especially for users of oral contraception and others with antithrombin-III disorders. Coagulation and fibrin …
(ABSTRACT TRUNCATED AT 400 WORDS) A detailed review of the dynamic processes of coagulation and fibrinolysis precedes a discussion of clinic …
Anti-heparin/PF4 complexes by ELISA in patients with disseminated intravascular coagulation.
Matsuo T, Matsuo M, Sugimoto T, Wanaka K. Matsuo T, et al. Pathophysiol Haemost Thromb. 2007;36(6):305-10. doi: 10.1159/000296281. Epub 2010 Mar 13. Pathophysiol Haemost Thromb. 2007. PMID: 20224256
We measured the titers of anti-PF4/hepatin complex antibodies by ELISA (HIT-Elisa) and examined 4 parameters of coagulation and fibrinolysis [D-dimer, thrombin/antithrombin complex (TAT), plasmin/alpha2-plasmin inhibitor complex (PIC), and antithrombin
We measured the titers of anti-PF4/hepatin complex antibodies by ELISA (HIT-Elisa) and examined 4 parameters of coagulation and fibrinolysis …
30 results